Simulation modeling in a panel of 2500 FOLFIRINOX-treated patients, using varying treatment duration (1–12 cycles) and conversion rates (10–100%), to estimate cost-savings and additional FOLFIRINOX treatment that could be budget neutral. Read more . . .
To estimate the cost-savings from conversion to biosimilar pegfilgrastim-cbqv that can be reallocated to provide budget-neutral expanded access to FOLFIRINOX in patients with metastatic pancreatic cancer.